A retrospective study of oral tofacitinib therapy for alopecia areata
Anais Brasileiros de Dermatologia · 2023
DOI: 10.1016/j.abd.2022.05.002 ↗Kurz gefasst
Fallbericht in der Zeitschrift Anais Brasileiros de Dermatologia, 2023. Verfasst von Xinaida Taligare Vasconcelos Lima und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Unit for Research Trials in Skin, Massachusetts General Hospital, Boston, Massachusetts, United States; Dermatology Division, Internal Medic…. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
lopecia Areata (AA) is an autoimmune non-scarring alopeia with an overall prevalence of around 2%.1 Treatment of oderate to severe AA is challenging. Retrospective studes have demonstrated that tofacitinib may induce hair egrowth in patients with moderate to severe AA.2--7 While he safety and efficacy of tofacitinib in severe AA were suported in these studies, the durability of treatment has not een extensively documented. In this retrospective cohort study, approved by Mass Genral Brigham Institutional Review Board, the authors have ystematically explored the long-term efficacy, safety, and urability of tofacitinib for the treatment of AA. The authors ere also interested in evaluating the impact of the tempoary discontinuation of tofacitinib on the course of AA during he COVID pandemic. ble patients had a diagnosis of AA and received systemic tofacitinib for a minimum of three months (Fig. 1). Diagnosis of AA was confirmed by a review of the patient’s medical record. All patients had AA for at least six months and were followed by a dermatologist. Information on the severity or proportion of scalp involvement, when available, was collected from dermatologist notes. Most of the patients excluded never started tofacitinib (lack coverage or safety concerns). Others had not been seen after tofacitinib had been prescribed, were taking tofacitinib for another indication, and did not have concomitant AA. Treatment response was categorized as complete (almost or total regrowth) and non-complete (partial or minimum), based on the providers’ notes. The authors evaluated demographics and disease characteristics between complete and non-complete using Mann-Whitney and Fisher Exact (SPSS 20.2, IBM, Armonk, NY).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Unit for Research Trials in Skin, Massachusetts General Hospital, Boston, Massachusetts, United States; Dermatology Division, Internal Medicine Department, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
- Clinical Unit for Research Trials in Skin, Massachusetts General Hospital, Boston, Massachusetts, United States.
- Clinical Unit for Research Trials in Skin, Massachusetts General Hospital, Boston, Massachusetts, United States. Electronic address: harvardskinstudies@mgh.harvard.edu.
Zitieren
APA
Lima, X. T. V., Bambery, M., & Alora, M. B. (2023). A retrospective study of oral tofacitinib therapy for alopecia areata. Anais Brasileiros de Dermatologia. https://doi.org/10.1016/j.abd.2022.05.002
Vancouver
Lima XTV, Bambery M, Alora MB. A retrospective study of oral tofacitinib therapy for alopecia areata. Anais Brasileiros de Dermatologia. 2023. doi:10.1016/j.abd.2022.05.002
BibTeX
@article{Lima2023,
author = {Lima, Xinaida Taligare Vasconcelos and Bambery, Melissa and Alora, Maria Beatrice},
title = {A retrospective study of oral tofacitinib therapy for alopecia areata},
journal = {Anais Brasileiros de Dermatologia},
year = {2023},
doi = {10.1016/j.abd.2022.05.002}
}
EUVIMED